Recombinant human interferon alpha 2b prevents and reverses experimental pulmonary hypertension

PLoS ONE

Volumn 9, Issue 5, 2014, Pages

  Bauer, Eileen M ^a,b   Zheng, Han ^a   Lotze, Michael T ^a,b   Bauer, Philip M ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INTERFERON RECEPTOR; RECOMBINANT ALPHA2B INTERFERON; ALPHA BETA INTERFERON RECEPTOR; ALPHA INTERFERON; ALPHA2B INTERFERON; RECOMBINANT PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTERIOLE; ARTICLE; CELL PROLIFERATION; CONTROLLED STUDY; DISEASE COURSE; DRUG BLOOD LEVEL; DRUG INHIBITION; EXPERIMENTAL HYPERTENSION; EXPERIMENTAL PULMONARY HYPERTENSION; HEART RIGHT VENTRICLE; HEART RIGHT VENTRICLE HYPERTROPHY; HUMAN; HUMAN CELL; HYPOXIA; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; MALE; MORPHOMETRICS; MOUSE; NONHUMAN; PATHOGENESIS; PULMONARY HYPERTENSION; RAT; SMOOTH MUSCLE FIBER; SYSTOLIC BLOOD PRESSURE; ANALYSIS OF VARIANCE; ANIMAL; ANOXIA; C57BL MOUSE; CELL CULTURE; COMPLICATION; DRUG EFFECTS; GENETICS; HEART VENTRICLE PRESSURE; HYPERTENSION, PULMONARY; KNOCKOUT MOUSE; METABOLISM; NICK END LABELING; PATHOLOGY; PHYSIOLOGY; VASCULAR REMODELING; WESTERN BLOTTING;

ANALYSIS OF VARIANCE; ANIMALS; ANOXIA; BLOTTING, WESTERN; CELLS, CULTURED; HUMANS; HYPERTENSION, PULMONARY; HYPERTROPHY, RIGHT VENTRICULAR; IMMUNOHISTOCHEMISTRY; IN SITU NICK-END LABELING; INTERFERON-ALPHA; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; RATS; RECEPTOR, INTERFERON ALPHA-BETA; RECOMBINANT PROTEINS; VASCULAR REMODELING; VENTRICULAR PRESSURE;

EID: 84901350304     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0096720     Document Type: Article

References (52)

1. Voelkel NF, Tuder RM (1995) Cellular and molecular mechanisms in the pathogenesis of severe pulmonary hypertension. Eur Respir J 8: 2129-2138.
2. Voelkel NF, Tuder RM (2000) Hypoxia-induced pulmonary vascular remodeling: a model for what human disease? J Clin Invest 106: 733-738.
3. Tuder RM, Groves B, Badesch DB, Voelkel NF (1994) Exuberant endothelial cell growth and elements of inflammation are present in plexiform lesions of pulmonary hypertension. Am J Pathol 144: 275-285. (Pubitemid 24165948)
4. Lee SD, Shroyer KR, Markham NE, Cool CD, Voelkel NF, et al. (1998) Monoclonal endothelial cell proliferation is present in primary but not secondary pulmonary hypertension. J Clin Invest 101: 927-934. (Pubitemid 28125268)
5. Masri FA, Xu W, Comhair SA, Asosingh K, Koo M, et al. (2007) Hyperproliferative apoptosis-resistant endothelial cells in idiopathic pulmonary arterial hypertension. Am J Physiol Lung Cell Mol Physiol 293: L548-554. (Pubitemid 47358814)
6. Fijalkowska I, Xu W, Comhair SA, Janocha AJ, Mavrakis LA, et al. (2010) Hypoxia inducible-factor1alpha regulates the metabolic shift of pulmonary hypertensive endothelial cells. Am J Pathol 176: 1130-1138.
7. Hanahan D, Weinberg RA (2011) Hallmarks of cancer: the next generation. Cell 144: 646-674.
8. Isaacs A, Lindenmann J, Valentine RC (1957) Virus interference. II. Some properties of interferon. Proc R Soc Lond B Biol Sci 147: 268-273.
9. Isaacs A, Lindenmann J (1957) Virus interference. I. The interferon. Proc R Soc Lond B Biol Sci 147: 258-267.
10. Mogensen KE, Lewerenz M, Reboul J, Lutfalla G, Uze G (1999) The type I interferon receptor: structure, function, and evolution of a family business. J Interferon Cytokine Res 19: 1069-1098. (Pubitemid 29502774)
11. Pfeffer LM, Dinarello CA, Herberman RB, Williams BR, Borden EC, et al. (1998) Biological properties of recombinant alpha-interferons: 40th anniversary of the discovery of interferons. Cancer Res 58: 2489-2499. (Pubitemid 28275413)
12. Dhillon S, Kaker A, Dosanjh A, Japra D, Vanthiel DH (2010) Irreversible pulmonary hypertension associated with the use of interferon alpha for chronic hepatitis C. Dig Dis Sci 55: 1785-1790.
13. Jochmann N, Kiecker F, Borges AC, Hofmann MA, Eddicks S, et al. (2005) Long-term therapy of interferon-alpha induced pulmonary arterial hypertension with different PDE-5 inhibitors: a case report. Cardiovasc Ultrasound 3: 26.
14. Fruehauf S, Steiger S, Topaly J, Ho AD (2001) Pulmonary artery hypertension during interferon-alpha therapy for chronic myelogenous leukemia. Ann Hematol 80: 308-310. (Pubitemid 32515055)
15. Olin J, Abman S, Grady R, Ivy D, Lovell M, et al. (2011) A 7-year-old with pulmonary hypertension. BMJ Case Rep 2011: bcr0220113843.
16. Almagro P, Julia J, Sanjaume M, Gonzalez G, Casalots J, et al. (2002) Pulmonary capillary hemangiomatosis associated with primary pulmonary hypertension: report of 2 new cases and review of 35 cases from the literature. Medicine (Baltimore) 81: 417-424. (Pubitemid 35285961)
17. Muller U, Steinhoff U, Reis LF, Hemmi S, Pavlovic J, et al. (1994) Functional role of type I and type II interferons in antiviral defense. Science 264: 1918-1921. (Pubitemid 24245635)
18. Siddegowda NK, Kumar Rao NS, Andrade C (2011) Development of a murine animal model of depression for repeated dosing with human interferon alpha. Indian J Psychiatry 53: 239-243.
19. Cao B, Chen XP, Zhu P, Ding L, Guan J, et al. (2008) Inhibitory effect of interferon-alpha-2b on expression of cyclooxygenase-2 and vascular endothelial growth factor in human hepatocellular carcinoma inoculated in nude mice. World J Gastroenterol 14: 6802-6807.
20. Cruz JA, Bauer EM, Rodriguez AI, Gangopadhyay A, Zeineh NS, et al. (2012) Chronic hypoxia induces right heart failure in caveolin-1-/- mice. Am J Physiol Heart Circ Physiol 302: H2518-2527.
21. Bauer EM, Zheng H, Comhair S, Erzurum S, Billiar TR, et al. (2011) Complement C3 deficiency attenuates chronic hypoxia-induced pulmonary hypertension in mice. PLoS One 6: e28578.
22. Ezekowitz RA, Mulliken JB, Folkman J (1992) Interferon alfa-2a therapy for life-threatening hemangiomas of infancy. N Engl J Med 326: 1456-1463.
23. Tarhini AA, Gogas H, Kirkwood JM (2012) IFN-alpha in the treatment of melanoma. J Immunol 189: 3789-3793.
24. Abe K, Toba M, Alzoubi A, Ito M, Fagan KA, et al. (2010) Formation of plexiform lesions in experimental severe pulmonary arterial hypertension. Circulation 121: 2747-2754.
25. Nicolls MR, Mizuno S, Taraseviciene-Stewart L, Farkas L, Drake JI, et al. (2012) New models of pulmonary hypertension based on VEGF receptor blockade-induced endothelial cell apoptosis. Pulm Circ 2: 434-442.
26. Sakao S, Taraseviciene-Stewart L, Lee JD, Wood K, Cool CD, et al. (2005) Initial apoptosis is followed by increased proliferation of apoptosis-resistant endothelial cells. FASEB J 19: 1178-1180. (Pubitemid 40946457)
27. Taraseviciene-Stewart L, Kasahara Y, Alger L, Hirth P, Mc Mahon G, et al. (2001) Inhibition of the VEGF receptor 2 combined with chronic hypoxia causes cell death-dependent pulmonary endothelial cell proliferation and severe pulmonary hypertension. FASEB J 15: 427-438. (Pubitemid 32141434)
28. Vandivier RW, Henson PM, Douglas IS (2006) Burying the dead: the impact of failed apoptotic cell removal (efferocytosis) on chronic inflammatory lung disease. Chest 129: 1673-1682. (Pubitemid 43895000)
29. Van Vre EA, Ait-Oufella H, Tedgui A, Mallat Z (2012) Apoptotic cell death and efferocytosis in atherosclerosis. Arterioscler Thromb Vasc Biol 32: 887-893.
30. Hodge S, Hodge G, Scicchitano R, Reynolds PN, Holmes M (2003) Alveolar macrophages from subjects with chronic obstructive pulmonary disease are deficient in their ability to phagocytose apoptotic airway epithelial cells. Immunol Cell Biol 81: 289-296. (Pubitemid 36904336)
31. Vandivier RW, Ogden CA, Fadok VA, Hoffmann PR, Brown KK, et al. (2002) Role of surfactant proteins A, D, and C1q in the clearance of apoptotic cells in vivo and in vitro: calreticulin and CD91 as a common collectin receptor complex. J Immunol 169: 3978-3986.
32. Vandivier RW, Fadok VA, Ogden CA, Hoffmann PR, Brain JD, et al. (2002) Impaired clearance of apoptotic cells from cystic fibrosis airways. Chest 121: 89S. (Pubitemid 34248373)
33. Simpson JL, Gibson PG, Yang IA, Upham J, James A, et al. (2013) Impaired macrophage phagocytosis in non-eosinophilic asthma. Clin Exp Allergy 43: 29-35.
34. Fernandez-Boyanapalli R, Goleva E, Kolakowski C, Min E, Day B, et al. (2012) Obesity impairs apoptotic cell clearance in asthma. J Allergy Clin Immunol 131: 1041-1047.
35. Bauer EM, Shapiro R, Zheng H, Ahmad F, Ishizawar D, et al. (2013) High Mobility Group Box 1 Contributes to the Pathogenesis of Experimental Pulmonary Hypertension via Activation of Toll-like Receptor 4. Mol Med 18: 1509-1518.
36. Bauer EM, Shapiro R, Billiar TR, Bauer PM (2013) High mobility group Box 1 inhibits human pulmonary artery endothelial cell migration via a Toll-like receptor 4- and interferon response factor 3-dependent mechanism(s). J Biol Chem 288: 1365-1373.
37. Friggeri A, Yang Y, Banerjee S, Park YJ, Liu G, et al. (2010) HMGB1 inhibits macrophage activity in efferocytosis through binding to the alphavbeta3-integrin. Am J Physiol Cell Physiol 299: C1267-1276.
38. Banerjee S, Friggeri A, Liu G, Abraham E (2010) The C-terminal acidic tail is responsible for the inhibitory effects of HMGB1 on efferocytosis. J Leukoc Biol 88: 973-979.
39. Liu G, Wang J, Park YJ, Tsuruta Y, Lorne EF, et al. (2008) High mobility group protein-1 inhibits phagocytosis of apoptotic neutrophils through binding to phosphatidylserine. J Immunol 181: 4240-4246.
40. Henson PM, Bratton DL, Fadok VA (2001) Apoptotic cell removal. Curr Biol 11: R795-805. (Pubitemid 32931008)
41. Chen BD, Najor F (1987) Macrophage activation by interferon alpha + beta is associated with a loss of proliferative capacity: role of interferon alpha + beta in the regulation of macrophage proliferation and function. Cell Immunol 106: 343-354. (Pubitemid 17106567)
42. Rollag H, Degre M, Sonnenfeld G (1984) Effects of interferon-alpha/beta and interferon-gamma preparations on phagocytosis by mouse peritoneal macrophages. Scand J Immunol 20: 149-155. (Pubitemid 14061736)
43. Ormiston ML, Chang C, Long LL, Soon E, Jones D, et al. (2012) Impaired natural killer cell phenotype and function in idiopathic and heritable pulmonary arterial hypertension. Circulation 126: 1099-1109.
44. Hervas-Stubbs S, Perez-Gracia JL, Rouzaut A, Sanmamed MF, Le Bon A, et al. (2011) Direct effects of type I interferons on cells of the immune system. Clin Cancer Res 17: 2619-2627.
45. Liang S, Wei H, Sun R, Tian Z (2003) IFNalpha regulates NK cell cytotoxicity through STAT1 pathway. Cytokine 23: 190-199. (Pubitemid 38340386)
46. Mattei D, Feola M, Orzan F, Mordini N, Rapezzi D, et al. (2009) Reversible dasatinib-induced pulmonary arterial hypertension and right ventricle failure in a previously allografted CML patient. Bone Marrow Transplant 43: 967-968.
47. Rasheed W, Flaim B, Seymour JF (2009) Reversible severe pulmonary hypertension secondary to dasatinib in a patient with chronic myeloid leukemia. Leuk Res 33: 861-864.
48. Dumitrescu D, Seck C, ten Freyhaus H, Gerhardt F, Erdmann E, et al. (2011) Fully reversible pulmonary arterial hypertension associated with dasatinib treatment for chronic myeloid leukaemia. Eur Respir J 38: 218-220.
49. Pullamsetti SS, Berghausen EM, Dabral S, Tretyn A, Butrous E, et al. (2012) Role of Src tyrosine kinases in experimental pulmonary hypertension. Arterioscler Thromb Vasc Biol 32: 1354-1365.
50. George PM, Oliver E, Dorfmuller P, Dubois OD, Reed DM, et al. (2014) Evidence for the involvement of type I interferon in pulmonary arterial hypertension. Circ Res 114: 677-688.
51. Wuttge DM, Lood C, Tufvesson E, Scheja A, Truedsson L, et al. (2013) Increased serum type I interferon activity in early systemic sclerosis patients is associated with antibodies against Sjogren's syndrome antigens and nuclear ribonucleoprotein antigens. Scand J Rheumatol 42: 235-240.
52. Eloranta ML, Franck-Larsson K, Lovgren T, Kalamajski S, Ronnblom A, et al. (2010) Type I interferon system activation and association with disease manifestations in systemic sclerosis. Ann Rheum Dis 69: 1396-1402.